**Trends in HRT use, percent decline from peak use, PAR% for breast cancer at peak HRT use, and screening age-range**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| *Country*  *Population*  *Age-range* | *HRT use*  *Percent (95% CI)* | | *Percent decline in HRT use (from peak)* | | *PAR% for breast cancer in postmenopausal women at peak HRT use and subsequent lowest HRT use* | | | *Eligible age for breast screening* |
| Australia  Population-based survey (n=907)  40 years and older | Peaked in 2001 at 21% (Decreased to 12% by 2002  Returned to 19% (15.6 – 22.2) by 2003 | | 43% by 2002  10% by 2003 | | 12.8%  7.7% | | | 40-75+  National programme |
| Canada  National Population Health Survey (n=1,200)  50-69 | Peaked at 30-45% in 2002  Decreased to 15% (13.0 – 18.9) by 2004 and 13.7% in 2006 | | 70% | | 24.0%  8.8% | | | 50-69  National programme |
| China  Shanghai Women’s Health Study cohort (n=74,942)  “after menopause” | Estimated 3% (2.9 – 3.1) in 1997-2000 | | n/a | | 2.1% | | | 40-59  National programme |
| Denmark  Danish Medicines Agency  Age range? | Peaked at 11% (10.96 – 11.0) in 2003  Decreased to 9.7% in 2004 and to 9% (8.9 – 9.03) in 2005 | | 19% | | 7.1%  5.7% | | | 50-69  State/regional programmes |
| Finland  Nationwide register study  45 years and older | Peaked at 21% (20.9 – 21.1) in 2003  Decreased to 12% (11.9 – 12.1) in 2012 | | 43% | | 12.8%  7.7% | | | 50-64  National programme |
| France  National reimbursement data  50-64 years | Peaked in 2001 at 32% (31.9 – 32.1) Decreased to 11% (10.97 – 11.03) by 2007 | | 66% | | 18.3%  7.1% | | | 50-74  National programme |
| Iceland  Survey (n=561)  47-53 years | 22% (18.6 – 25.6) in 2004  (Ref Icelandic study 57% of 52-57 year olds 1996-2001) | | 61% | | 13.3% | | | 40-69  National programme |
| Israel  HMO population (n=251,000)  45 years and older | | 20% (19.8 – 20.2) in 2001  10% (9.9 – 10.1) in 2007 | | 50% | | 12.3%  6.5% | 50-74  National programme | |
| Italy  Milan prescriptions file  50-69 years, and cross-sectional survey of screening population aged 50-69 (n=8533) | | Estimated at 12% in 2003  6.9% (6.4 – 7.5) in 1999-2001 | | 42% | | 7.7% | 50-69  National programme | |
| Japan  Community survey (n=8791)  45-64 years | | 2.5% (2.2 – 2.9) in 1992 | | n/a | | 1.7% | 40-75+  National programme | |
| Korea  Marketing data  50 years and older | | Decreased by 39% from 2002 to 2006, then ‘increased slightly’ to 2009. 4.5% (4.48 – 4.52) in 2010 | | 39% | | 3.1% (in 2010) | 40-75+  National programme | |
| Netherlands  EPIC Cohort (n=17,357)  49-70 years | | Peaked at 13% (12.5 – 13.5) 1993 - 1997  Decreased to 11.4% in 2002-2003 and to 6.6% (6.2 – 7.0) by 2005 | | 50% | | 8.3%  4.4% | 50-74  National programme | |
| New Zealand  Population-based survey (n=318)  45-64 years | | 20% (18.1 – 22.2) in 1997  Decreased to 11% (8.0 – 14.9) in 2002 | | 45% | | 12.3%  7.1% | 45-69  National programme | |
| Norway  Official Drug Statistics and Oslo Health Study (57% of Oslo women)  59-60 years | | 46% (41.8 – 49.6) of 59-60 year olds in 2000-2001 (Oslo)  Decreased in Norway by 67% from 1999 to 2007 | | 67% | | 24.4% | 50-69  National programme | |
| Poland  Representative national sample (n=1,544)  45-64 years | | 12% (10.4 – 13.7) in 2002 (before WHI Trial results) | | n/a | | 7.7% | 50-69  National programme | |
| Portugal  Cohort (n=382)  “Postmenopausal” | | Lifetime prevalence of HRT use unchanged from 1985-2005 | | n/a | | - | 45-69  State/regional programmes | |
| Saudi Arabia  Tertiary care hospital chart review (n=144)  56-59 years | | 46% (47.7 – 54.0) in 2000 (before WHI Trial results) | | n/a | | 24.4% | 40-64  State/regional programmes | |
| Spain  Primary healthcare centre population (n=371)  45-65 years | | 11% (10.7 – 11.0) in 1998  8.6% (5.8 – 11.5) in 2002 | | 22% | | 7.1%  5.7% | 50-69 (Catalonia)  45-69 (Navarra) | |
| Sweden  National pharmacy data  50-59 years | | Peaked at 36% (35.9 – 36.1) in 1999  Declined to 27% in 2002 and 9% (8.9 – 9.1) in 2007 | | 75% | | 20.1%  5.9% | 40-74  State/regional programmes | |
| Switzerland  Swiss Drug Register  45-49 years | | 29.8 (29.7 – 29.9) in Switzerland and 50% (49.7 – 50.7) in Geneva in 1996  46% in 2002 | | n/a | | 25.9%  24.4% | 50-69  National programme | |
| United Kingdom  Million Women Study  45-69 years | | 27.7% (27.7 – 27.9) in 1998  25% in 2000-2001  12% (11.9 – 12.1) in 2006 | | 57% | | 16.2%  7.7% | 50-69  National programme | |
| United States  National prescription and therapeutic index databases  50-74 years | | Peaked at 42% (42.00 – 42.04) in 2001  Declined to 28% (28.00 – 23.02) in 2003 | | 33% | | 22.7%  16.4% | 40-75+  N/A | |

RR for HRT use and breast cancer = 1.7 (95% CI 1.6 – 1.8).